<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-announces-tepkinly-epcoritamab-in-combination-with-lenalidomide-and-rituximab-is-approved-by-the-european-commission-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-302818589.html">AbbVie kündigt an: TEPKINLY® (epcoritamab) in Kombination mit Lenalidomid und Rituximab von der Europäischen Kommission zur Behandlung von rezidivierendem oder refraktärem follikulärem Lymphom zugelassen</a>
    </div>

      <div class="me-0 me-md-5">
        TEPKINLY® (epcoritamab) plus Lenalidomid und Rituximab (R2) ist die erste und einzige auf Bispezifika basierende Therapie, die in Europa zur Behandlung von rezidivierendem oder refraktärem follikulärem Lymphom im Zweitlinien-Setting zugelassen ist und eine chemotherapiefreie Option bietet. In der Phase-3-ZULASSUNGSSTUDIE EPCORE® FL-1 erreichten die TEPKINLY + R2 mit fester Behandlungsdauer eine...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1094734?SNAPI">Merck, AbbVie probed by US lawmakers over China clinical trials: report</a>
    </div>

      <div class="me-0 me-md-5">
        A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country&#39;s military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of th...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-announces-positive-phase-3-results-for-epcoritamab-plus-lenalidomide-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-302813689.html">AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma</a>
    </div>

      <div class="me-0 me-md-5">
        Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regim...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-and-adolescents-with-severe-alopecia-areata-302812437.html">AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata</a>
    </div>

      <div class="me-0 me-md-5">
        Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 24 1,2 Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-and-adolescents-with-non-segmental-vitiligo-302812429.html">AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo</a>
    </div>

      <div class="me-0 me-md-5">
        If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease Positive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in which upadacitinib achieved both co-primary endpoints demonstrating at least a 50% impr...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-302812335.html">SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease</a>
    </div>

      <div class="me-0 me-md-5">
        SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and ol...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Market Watch</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketwatch.com/story/healthcare-stocks-have-become-a-haven-for-investors-ditching-tech-81c544d0">Healthcare stocks have become a haven for investors ditching tech</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of AbbVie, Eli Lilly and Johnson &amp; Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Forbes</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.forbes.com/sites/innovationrx/2026/06/24/abbvies-11-billion-immunology-bet/">AbbVie&#39;s $11 Billion Immunology Bet</a>
    </div>

      <div class="me-0 me-md-5">
        In this week&#39;s edition of InnovationRx, we look at AbbVie&#39;s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get it in your inbox, subscribe here.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/AbbVie-US00287Y1091/load_more?page=6">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>